Innovation

A Biomarker of Heart Failure in Type-2 Diabetes Mellitus; An Effective Target for Diagnostic Purposes and Therapeutic Strategies

University of California System: University of California, Davis - UC Davis
posted on 06/18/2010

Brief description unavailable

Suggested Uses

These findings have immediate relevance for individuals susceptible to develop cardiac dysfunction in pre-diabetes, when this biomarker has increased propensity to form and accumulate in the heart. These individuals can benefit from improved prognosis and development of new treatments.


Innovation Details
 

Detailed Description

Cardiac dysfunction is the leading cause of death (> 50%) in diabetic and pre-diabetic population. However, the specific molecular mechanisms underlying diabetic heart failure remain largely unknown. To date, there is no heart failure diagnostic method or treatment specific to diabetes, even though diabetic heart failure has a poor prognosis. Researchers at University of California, Davis have indentified the islet amyloid polypeptide (IAPP) oligomer, a toxic entity causally implicated in dysfunction of pancreatic β-cells and development of type-2 diabetes mellitus (T2DM), as the primary molecular pathogen linking T2DM to heart failure. UC Davis researchers have discovered that secretory dysfunction of pancreatic β-cells leading to the formation of IAPP toxic oligomers results in a feed forward process, whereby the secretion of these toxic entities in the blood causes additional damage in organs other than pancreas, including heart and kidneys. Thus, these toxic oligomers represent pathogens of diabetic cardiac dysfunction. Researchers have shown that accumulation of IAPP toxic oligomers in the heart triggers a cascade of structural and physiological changes within myocytes culminating in heart failure. The discovery that the IAPP toxic oligomer is a biomarker of heart failure in T2DM has immediate relevance in the diagnosis and prognosis of cardiac dysfunction in T2DM and pre-diabetic patients.

The UC Davis researchers’ findings reveal that the toxicity associated with accumulation IAPP oligomers in the heart manifests starting from early pre-diabetes. Thus, these oligomers may represent an effective target for diagnostic purposes and therapeutic strategies.

File Number: 20953 

Disease: Cardiovascular and Circulatory System

Other Information:

ABSTRACT

The primary molecular pathogen contributing to cardiac dysfunction in type-2 diabetes mellitus (T2DM) patients.

Features/Benefits
  • Novel Diabetic Cardiomyopathy Diagnostics
  • Targeted Therapies


IP Protection

Copyright: ©2010, The Regents of the University of California

License Online

This innovation currently is not available for online licensing. Please contact Nancy Rashid at University of California System: University of California, Davis - UC Davis for more information.

Request more info via email request more info
People

Case Manager:

Nancy Rashid Nancy Rashid

Innovations (42)


Download Technology Brief (PDF)


Followed By

Follow this innovation



No one is following this innovation.

Organization
Profile
Related Tags

Find more innovations


February 11, 2009

7,868 members 17,196 innovations 152 organizations

Browse

Dr. Jörg Knäblein – Technology Scouting, Bayer Schering Pharma AG

"Through the iBridge Network, I was able to find a mouse model I was looking for. The collaboration available through the iBridge Network is crucial in driving innovation and I'll continue using it as a valued resource."  read more...